Table 2.
Multivariate analysis of clinicopathological model, Model 2 (the early-treatment model) and Model 3 (the posttreatment model)
| Clinicopathological model | p-value | Model 2 | p-value | Model 3 | p-value | ||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95%CI | OR | 95%CI | OR | 95%CI | ||||
| Ki67 | |||||||||
| Negative | Reference | ||||||||
| Positive | 1.436 | 0.783–2.633 | 0.240 | 1.716 | 0.815–3.615 | 0.153 | 1.985 | 0.858–4.594 | 0.107 |
| ER | |||||||||
| Negative | Reference | ||||||||
| Positive | 0.742 | 0.333–1.657 | 0.465 | 0.559 | 0.212–1.470 | 0.236 | 0.700 | 0.242–2.024 | 0.509 |
| PR | |||||||||
| Negative | Reference | ||||||||
| Positive | 0.990 | 0.427–2.302 | 0.984 | 0.701 | 0.258–1.904 | 0.484 | 0.768 | 0.231–2.548 | 0.664 |
| Her2 | |||||||||
| Negative | Reference | ||||||||
| Positive | 0.937 | 0.078–11.320 | 0.959 | 1.062 | 0.369–3.055 | 0.911 | 1.036 | 0.063–16.92 | 0.980 |
| Subtype | |||||||||
| Triple-negative | Reference | ||||||||
| HER2(+) | 2.047 | 0.161–25.97 | 0.578 | 1.375 | 0.083–22.90 | 0.823 | 1.271 | 0.075–21.44 | 0.867 |
| HER2(−)&HR(+) | 1.194 | 0.361–3.945 | 0.770 | 1.275 | 0.305–5.331 | 0.738 | 1.378 | 0.272–6.987 | 0.697 |
| P0-Signature | – | – | – | 2.357 | 1.531–3.629 | < 0.001 | 1.881 | 1.222–2.894 | 0.004 |
| P1-Signature | – | – | – | 2.455 | 1.721–3.502 | < 0.001 | 2.094 | 1.468–2.987 | < 0.001 |
| P2-Signature | – | – | – | – | – | – | 2.097 | 1.543–2.849 | < 0.001 |
Model 2 was built based on the P0-Signature plus the P1-Signature. And Model 3 was based on Model 2 plus the P2-Signature
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor, P0 Phase 0 (pretreatment), P1 Phase 1 (early-stage treatment, namely, during the first–second cycle of the neoadjuvant chemotherapy), P2 Phase 2 (posttreatment), OR odds ratio, 95%CI 95% confidence interval